Large-Scale Study of Clinical Impact of PSA Velocity: Long-Term PSA Kinetics as Method of Differentiating Men with from Those without Prostate Cancer

Urology

Volumn 69, Issue 1, 2007, Pages 134-138

  Berger, Andreas P ^a   Deibl, Martina ^a   Strasak, Alexander ^a   Bektic, Jasmin ^a   Pelzer, Alexandre E ^a   Klocker, Helmut ^a   Steiner, Hannes ^a   Fritsche, Gernot ^b   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SCREENING; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GLEASON SCORE; HUMAN; KINETICS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33846511006     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.018     Document Type: Article

References (12)

1. Labrie F., Dupont A., Suburu R., et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147 (1992) 846-852
2. Labrie F., Candas B., Cusan L., et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 47 (1996) 212-217
3. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279 (1998) 1542-1547
4. Carter H.B., Pearson J.D., Metter M.D., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
5. Smith D., and Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163-1167
6. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
7. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
8. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate specific antigen in a community-based population of healthy men: establishment of age specific reference ranges. JAMA 270 (1993) 860-864
9. Reissigl A., Horninger W., Fink K., et al. Prostate carcinoma screening in the federal state of Tyrol, Austria. Cancer 80 (1997) 1818-1829
10. Fang J., Metter E.J., Landis P., et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology 59 (2002) 889-894
11. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
12. Moul J.W. Thresholds for prostate cancer detection. JAMA 278 (1997) 699